Navigation Links
New data showed Actos prevented progression of atherosclerotic plaque volume in patients
Date:3/31/2008

Chicago, IL, March 31, 2008 New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS® (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial.

The PERISCOPE trial was presented today as a late breaker at the 57th Annual Scientific Session of the American College of Cardiology in Chicago. This trial adds to the body of cardiovascular data for ACTOS. ACTOS studies, conducted over the past 10 years in more than 16,000 patients, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

We are pleased with the results of the PERISCOPE, which further expands our cardiovascular data with ACTOS, said David P. Recker, M.D., senior vice president, Clinical Sciences and interim president at Takeda Global Research & Development. While not definitive, data from PERISCOPE combined with results from a previous study, looking at surrogate endpoints, have shown a consistent trend toward decreasing cardiovascular risk by reducing the atherosclerotic burden in people with type 2 diabetes.

PERISCOPE is the first clinical trial to examine the effects of an oral antidiabetic medication on the development of coronary atherosclerosis in patients with type 2 diabetes using IVUS technology. The trial conducted in 97 centers in the U.S., Canada and Latin America with 543 patients, used IVUS imaging of the coronary arteries. The analysis demonstrated a statistically significant difference in percent change in coronary artery atheroma volume in favor of ACTOS treatment compared to glimepiride t
'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
917-865-6688
Takeda Pharmaceuticals North America
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
2. Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
3. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
4. New study of Concerta showed significant improvement of ADHD symptom management in adults
5. African Americans at Risk for Low Calcium Intake - New Survey Finds Those Experiencing Symptoms of Lactose Intolerance May be Sidelining Dairy in Their Diets
6. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
7. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
8. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
9. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
10. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
11. One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...aunched a series of clinical trials in order to as...his approach involves the application of personali...s from the patient him or herself and designed to ...nd frequent malignant tumours. The new therapy is ...th the standard, first-line treatment involving su...
(Date:11/30/2009)...do knees, internal injuries, study finds, , ...re a middle-age weekend warrior who likes to hit t...ew study suggests that high levels of physical act...could lead to osteoarthritis. , The study found...ho showed no symptoms and had a healthy weight. Th...
(Date:11/30/2009)...giving catalog to help families make charitable gi... 30 In spite of the eco...y season willing to support charities in two ways,...wn wallets to support charities and nearly 40 perc...instead of buying them a gift, according to a new ...
(Date:11/30/2009)...ewswire-FirstCall/ -- Stryker Corporation (NYSE: ...acquire privately held Ascent Healthcare Solutions...emanufacturing of medical devices in the U.S. ,...acquire Ascent Healthcare Solutions for $525 milli...itioned on the expiration or termination of all ap...
(Date:11/30/2009)...k up , , MONDAY, Nov. 30 (HealthDay News...e U.S. Congress differ in a number of ways but ach...mber of uninsured Americans. , Legislation appr...month would expand coverage to 96 percent of Ameri... to expand coverage to 94 percent of Americans. ,...
Breaking Medicine News(10 mins):Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 3Health News:American Red Cross Survey Finds 62 Percent of Americans Plan to Donate More Than $25 to Charity This Holiday Season in Spite of Economic Downturn 2Health News:American Red Cross Survey Finds 62 Percent of Americans Plan to Donate More Than $25 to Charity This Holiday Season in Spite of Economic Downturn 3Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 2Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 3Health News:Health Reform: What's in It for You? 2Health News:Health Reform: What's in It for You? 3
...enefits of Frameless Delivery and Fractionation De... Preservation , , SUNNYVALE, Calif., May 5 Accur... in the field of radiosurgery, announced today tha...ion of Neurological Surgeons (AANS) Annual Meeting...
...nline and Phone Based Survey Encourages Nurses to ...areers , , , PORTLAND, Ore., May 5 Vigilan, the...brates National Nurse Week May 6-12, 2009 by liste...ementia care. Vigilan is offering an online and p...
...ONDON, May 5 Initiatives taken by European govern...ion surveillance systems have aimed at improving e...r, the lack of basic level automation is proving t...ts across Europe to install infection surveillance...
...ADISON HEIGHTS, Mich., May 5 InfuSystem Holdings... the leading provider of ambulatory infusion pumps... financial results and provided a business update ...e first quarter of 2009, despite a nationwide shor...
...irst Diagnostic Test for Identifying E. coli, K. p... Blood Cultures , , PNA FISH Provides Critical Re... to Help Clinicians Improve Care and Outcomes for ...0(k) clearance for EK/ P. aeruginosa PNA FISH(R) ...
... , , REDWOOD CITY, Calif., May 5 Ingenuity Syste...for life science researchers, today announced a mu...plans to expand the utilization of IPA in its rese... researchers plan to leverage the powerful analysi...
Other Medicine News:Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 2Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 3Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 4Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 5Health News:Vigilan Honors National Nurse Week in Assisted Living, Independent Living and Dementia Care 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 3Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 2Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 3Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 4Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 5Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 6Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 7Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 2Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 3Health News:Ingenuity Systems Announces Multi-Year Deal With AstraZeneca 2Health News:Ingenuity Systems Announces Multi-Year Deal With AstraZeneca 3
(Date:11/30/2009)..., WALTHAM, Mass., Nov. 30 Decis... and advisory firms focusing on pharmaceutical and... virus drug market in Russia will grow nine percen...hing $327 million by 2013. This growth will be dri...lthcare and increased use of more-expensive therap...
(Date:11/30/2009)... , INDIANAPOLIS, Nov. 30 /PRNewswire-FirstCall...as approved Cymbalta® (duloxetine HCl) for th...order (GAD) in adults, Eli Lilly and Company (NYSE...d anxiety disorder can be a chronic illness, it is...treatment option that is effective in both the acu...
(Date:11/30/2009)..., BRIDGEWATER, N.J., Nov. 30 /PRNewswire-FirstCall...ng of an exclusive licensing agreement with Intell...for the emergency treatment of allergic reactions ... ,, "We are pleased to have this opportunity to...lions of people who are at risk of this life-threa...
Breaking Medicine Technology:Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 2Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 3China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 1China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 2China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 3China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 4China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 5China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 6China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 7China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 8China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 9China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 10China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 11China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 12China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 13Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 4928 1Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 4928 2MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 1MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 2MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 3MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 4
... American Association for Cancer Research,annual m...ire-FirstCall/ --,Medarex, Inc. today presented pr...tivity from two separate studies exploring the,eff... anti-CD70,antibody-drug conjugates. CD19 and CD70...conjugate approach to cancer therapy. They are,exp...
...the American Association for Cancer Research,(AACR...- Lorus,Therapeutics Inc. ("Lorus") today announce... and siRNA compounds at the 98th,Annual Meeting of... The first presentation titled, "Determination of ...docetaxel combination,treatment for NSCLC cells in...
Other Medicine Technology:Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 2Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 3Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 4Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 5
Revo Rotator Cuff Repair System
BioROC EZ Fasteners and Instrumentation
...a fully absorbable soft tissue anchor designed spe...s dynamic engagement into cancellous bone, its bro...de significant resistance to pullout in soft bone....ction provides the benefits of fixation strength c...
...ade; Ti Quick-T Fixation System is a single-step t...r secondary tissue fixation. This through tendon t...e Anchor combined with our pretied knot technology...e of PEEK-OPTIMA® LT3 polymer from Invibio. Th...
Medicine Products: